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In 2007, the National Human Genome Research Institute (NHGRI) established the Electronic MEdical Records and
GEnomics (eMERGE) Consortium (www.gwas.net) to develop, disseminate, and apply approaches to research that com-
bine DNA biorepositories with electronic medical record (EMR) systems for large-scale, high-throughput genetic research.
One of the major ethical and administrative challenges for the eMERGE Consortium has been complying with existing
data-sharing policies. This paper discusses the challenges of sharing genomic data linked to health information in the
electronic medical record (EMR) and explores the issues as they relate to sharing both within a large consortium and in
compliance with the National Institutes of Health (NIH) data-sharing policy. We use the eMERGE Consortium experience
to explore data-sharing challenges from the perspective of multiple stakeholders (i.e., research participants, investigators,
and research institutions), provide recommendations for researchers and institutions, and call for clearer guidance from
the NIH regarding ethical implementation of its data-sharing policy.
Although data sharing among researchers has not always been
embraced, its importance is increasing with the advent of new
technological approaches requiring large data sets for analysis. To
facilitate broad data sharing from genome-wide association studies
(GWAS), the National Institutes of Health established the database
of Genotypes and Phenotypes (dbGaP) (Mailman et al. 2007) and
an accompanying GWAS Data-Sharing Policy (National Institutes
of Health 2007), which strongly encourages submission of data
from NIH-funded GWAS into dbGaP. As of November 2010, one
hundred twenty studies have submitted data into dbGaP, but little
is known about the experiences and perspectives of stakeholders
involved in the process.
In late 2007, the National Human Genome Research Insti-
tute (NHGRI) established the Electronic MEdical Records and
GEnomics (eMERGE) Consortium (www.gwas.net) to develop,
disseminate, and apply approaches to research that combine DNA
biorepositories with electronic medical record (EMR) systems for
large-scale, high-throughput genetic research (McCarty et al.
2011a). The Consortium comprises five sites: Group Health
Cooperative/University of Washington, Marshfield Clinic, Mayo
Clinic, Northwestern University, and Vanderbilt University. The
project includes a community consultation and ethics component
to study the unique ethical, legal, and social implications (ELSI) of
EMR-coupled biobanks (Clayton et al. 2010). A major focus of ELSI
research within the eMERGE Consortium has been to assess the
challenges of data sharing, as it is practiced both within the Con-
sortium and through the database of Genotypes and Phenotypes
(dbGaP), from the perspective of stakeholders involved in the
process (research subjects, genome scientists, and institutions).
This paper was written by a subcommittee of the Consent and
Community Consultation (C&CC) Working Group, which in-
cludes investigators from each eMERGE site and NIH Project
Leaders, as well as outside experts on the ethical and policy im-
plications of broad data sharing. This paper describes the eMERGE
experience with data sharing, presents several challenges to such
data sharing from the perspective of study investigators, and
summarizes participant perspectives on data sharing from site-
specific studies. The purpose of this paper is to illustrate what data
sharing actually entails and the ethical and practical challenges of
implementing established data-sharing policies from within
a multisite Consortium.
eMERGE data sharing
One of the goals of eMERGE is to develop methods for extracting
phenotype data from EMR systems for use in genome-wide as-
sociation studies (GWAS) that could, with minimal effort, be
implemented in various institutions and data systems. Work to-
ward this goal necessitated considerable collaboration between
sites as each implemented and tested algorithms developed by
other sites. Initially, data sharing in eMERGE was only anticipated
between individual sites on an ad hoc basis, as early collaborative
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efforts developed pairwise. One site would test the implementa-
tion of an electronic phenotype algorithm from another site. Such
efforts proved to be successful, and sites realized that cohort size
could be rapidly expanded by using subjects from other Consor-
tium sites. For example, Vanderbilt actively worked with North-
western to implement and validate Northwestern’s Type 2 diabetes
phenotype algorithm and were then able to contribute over 2000
primarily African-American research subjects from Vanderbilt to
the Northwestern study (Table 1).
To maximize these collaborations between sites, participating
institutions had to develop Data Use Agreements (DUA) in order to
share de-identified research data, including the Health Insurance
Portability and Accountability Act (HIPAA)-defined limited data
sets, with other sites within the Consortium. A DUA is a legal
agreement between institutions, in this case, signed by the in-
vestigators and the designated institutional officials from each of
the data-sharing organizations, that establishes what data may be
shared, the ways in which the information in the data set may be
used, and how the data will be protected. The DUA generally
describes the research project, types of data elements to be shared,
and who (or what classes of people, e.g., researchers and project
staff) have access to the specific data.
This early stage of eMERGE utilized site-specific and project-
specific DUAs, enabling data to be shared between pairs of insti-
tutions. Electronic phenotyping efforts were remarkably success-
ful, and all site-led studies included data from more than one
institution, thus increasing sample size and study power. The
Consortium quickly realized the strength and uniqueness of its
combined data set of over 17,000 GWAS subjects and the benefits
of sharing data across all sites to further increase the power of each
study and to provide viable replication data for promising associa-
tions (Fig. 1). Just as quickly, it became apparent that pairwise
DUAs constrained the ability of the Consortium to function
effectively, as sharing between more than two institutions became
a necessity for each new phenotyping project, requiring the de-
velopment of multiple DUAs for each study.
Further, six phenotypes were chosen for network-wide studies
that would leverage EMR data and genotype data from samples
originally analyzed for primary phenotypes. To enable these
analyses, the Administrative Coordinating Center (ACC), funded
within the grant and hosted by Vanderbilt University Medical
Center, facilitated the sharing of genotype and phenotype data
across all sites (see Fig. 1). For the network phenotypes, it was
agreed that the ACC would centralize phenotypic and genomic
data for network studies and facilitate the efficient flow of data
among all sites. To enable this activity, the ACC worked with
representatives from each site and developed a single DUA and
Memorandum of Understanding with language and content that
was agreeable to all Consortium members. This agreement allowed
data to be shared between each site and with the ACC and also,
critically, allowed the ACC to share all network data, including the
full genomic data set, with all sites, thus becoming a data hub.
All eMERGE sites also share data with the broader research
community by submitting phenotype and genotype data to
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dbGaP for each GWAS conducted. Data submission is largely the
responsibility of each site, although the ACC aggregated and
submitted all data for the larger Consortium projects. Regardless
of whether the data are submitted to dbGaP by the ACC for net-
work-wide studies or by individual sites for site-specific GWAS, all
subjects are identified by their site or study of origin, and the data
maintains any restrictions dictated by the original informed-
consent agreement.
All eMERGE sites have shared their primary study data with
dbGaP. The Consortium continues to evaluate systematically var-
ious risks of re-identification of participants based on the types of
data submitted to external databases like dbGaP and the policies
governing those databases. To date, eMERGE researchers have
developed a framework to understand events that might pre-
cipitate re-identification, including intentional attack (Benitez and
Malin 2010; Malin et al. 2010) and processes to mitigate this risk
(Malin et al. 2011). Researchers are also working to improve the
processes for submitting data, including collaborative submis-
sions, and to expand the various file types for submitting different
classes of data, such as medications, reimbursement codes, and
vital signs. In addition, the eMERGE experience suggests the need
for shorter, more simplified DUAs that are easy to implement,
provide clear safeguards for data, and can be expanded to include
new partners joining the Consortium. Such a document is cur-
rently being pilot tested within eMERGE.
Data-sharing challenges
The Request for Proposals for the eMERGE Consortium was pub-
lished in March 2007, and funding began in September 2007, one
year after dbGaP was established and one month after the notice
for the NIH Data Sharing Policy for Genome-Wide Association
Studies was first published in the federal register. Although the NIH
policy became effective only for competing applications and pro-
posals submitted after January 25, 2008,
the Request for Applications (RFA) de-
scribing the eMERGE program indicated
that eMERGE investigators and insti-
tutions would be expected to be in com-
pliance with the policy prior to funding.
eMERGE investigators faced several chal-
lenges as they sought to meet both new
expectations for broad data sharing
through dbGaP and the demands of
membership in the NIH Consortium. A
survey of all site PIs, plus the experi-
ence of the authors who participated in
decisions in real time, reveal how data-
sharing obligations were balanced with
institutional commitments to research
participants recruited at each site. Re-
searchers at each site encountered dif-
ferent challenges specific to the unique
nature of the institutional and commu-
nity context. Most of the challenges
researchers encountered can be loosely
categorized as administrative (or bu-
reaucratic) challenges and challenges in
honoring ethical obligations to study
participants and their communities. How-
ever, these categories intertwine as ad-
ministrative requirements are often put
in place to try to enforce or promote ethically responsible conduct
(Table 2).
As will be the case with any multisite consortium, harmoni-
zation across sites was a major challenge within eMERGE. Each site
had their own study protocol, and the Institutional Review Board
(IRB) at each site requested conditions or modifications based on
institutional policy and local concerns. Consent forms also varied
greatly. Since eMERGE was utilizing existing samples and clinical
data from each site, some sites had multiple consent forms that
were updated and changed over time. None of the consent docu-
ments specifically anticipated this type of research use of the
samples/data or the broad data sharing required by the NIH data-
sharing policy. In some cases, inconsistent institutional policies
resulted in disparate treatment of subjects. For example, despite
the fact that four of the five eMERGE sites originally obtained
broad consent for the collection and subsequent use of samples,
Figure 1. Data sharing for eMERGE is composed of three central tenets: (1) sharing of research data,
including genomic data, between sites; (2) sharing of research data among all sites and the Adminis-
trative Coordination Center (ACC) with the facilitation of data flow enabled by the ACC or any par-
ticular site; and (3) sharing of data with secondary investigators through external NIH databases,
namely dbGaP.
Table 2. Data-sharing challenges and policy considerations
Use of archived specimens creates special issues
Specimens collected over time, using multiple consents, with
evolving revisions
Lack of consistency across consortium sites in IRB determination
for need for re-contact and new consent for GWAS, federal data
sharing
Balancing compliance with NIH GWAS data-sharing policy with
site-specific responsibility for ethical review and data submission to
dbGaP
Varying levels of institutional preparedness for addressing GWAS data
sharing
Different existing policies for sharing research subject level data
outside the institution
Lack of harmonization of policies across sites for reviewing data and
certifying compliance with GWAS data-sharing policy
Inconsistent policies within an institution




the institutional review process at one of these sites resulted in
a requirement that investigators re-consent participants specifi-
cally for GWAS data sharing (Ludman et al. 2010). The IRB at the
three other sites determined that the broad consent originally
obtained from participants allowed data sharing. The last site did
not require informed consent because the design of their biobank
was found to be consistent with nonhuman subjects research.
Their model uses blood remaining from routine clinical care linked
to de-identified clinical data from the EMR (Roden et al. 2008). In
this model, patients are informed about the program when they
seek care and are informed that they may opt out of the program at
any time.
Inconsistency in IRB review and demands has long been a
source of frustration for investigators (and IRBs alike) and is seen as
a barrier to conducting multisite clinical trials (Menikoff 2010).
The problem is exacerbated by a national policy that expects broad
data sharing across studies, while placing responsibility for ethi-
cal review and coordination of the administrative aspects of data
submission with institutions and their human subjects protection
programs (e.g., IRBs or Privacy Boards). This intentionally allows
for community input but also invariably leads to variation in
policies and practices and tensions between federal and local re-
quirements that can be confusing for investigators (and IRBs)
collaborating within a large consortium.
Institutions conducting GWAS must also develop new poli-
cies and processes in order to comply with the NIH data-sharing
policy. For example, the policy expects that each institution pro-
vide certification that it approves submission of the data to dbGaP.
In order to sign such an agreement, the submitting institution’s
IRB and/or Privacy Board must review and certify that the in-
vestigator’s plan for de-identifying data sets prior to submission is
consistent with NIH policy, ensure that the uses and exclusions of
the data (i.e., data use limitations) are in accordance with what
participants agreed to during the informed consent process, and
certify that the genotype and phenotypes were collected in a
manner consistent with federal regulations (U. S. Dept. of Health
and Human Services 2009).
Little cross-site learning or standardization took place within
the eMERGE Consortium when completing the institutional certi-
fication due to variability in how prepared each submitting in-
stitution was to comply with federal policy and how they ultimately
chose to review and certify compliance with the NIH GWAS data-
sharing policy. At one site, the IRB had already developed a review
process and a template for institutional certification. At another, no
process was in place, but the IRB and institutional officials worked
together through the experience to develop a process that was
eventually incorporated into all electronic project submissions for
IRB approval. At several other institutions, there were no formal
processes in place, but investigators worked with their IRBs and/or
institutional officials to obtain institutional certification.
The lack of institutional preparedness to comply with
changing federal policy may reflect conflict with the ethical values
underlying how different sites treat data collected from the com-
munity. For example, some sites historically have established
a close and trusting relationship with the community, and there is
a strong tradition of never allowing subject-level information
outside of institutional walls. This must change for the institution
to conduct large NIH-funded GWAS or to participate in national
projects like eMERGE as long as the NIH continues to require broad
data sharing. However, some institutional officials and individual
investigators are reluctant to change their practices and share data
more broadly because they believe it would be inconsistent with
community expectations and desires and would, therefore, pose
a potential threat to public trust.
Complying with data-sharing policies can also make it diffi-
cult to respect the wishes of participants who prefer more limited
data sharing or would prefer that oversight of their samples and
data be more tightly controlled by the institution collecting sam-
ples and data. Effective implementation of data-sharing policies
should promote scientific progress while protecting participant
interests and preserving public trust. As part of the implementa-
tion process, each eMERGE site solicited input from participants
and community members in order to anticipate and respond ef-
fectively to ethical challenges raised by this sort of data sharing.
Stakeholder perspectives on data sharing
Each eMERGE site conducted independent community consulta-
tion activities and studies of stakeholders’ (largely research par-
ticipants’ and potential participants’) views. As summarized in
Table 3, activities ranged from notification of planned data sharing
via a study newsletter (Marshfield), consultation with study
Community Advisory Boards (Marshfield, Mayo, Northwestern,
Vanderbilt), solicitation of views as part of a community-based
deliberative democracy exercise (Mayo), interviews with study
participants and refusers (Mayo), focus groups with participants
and potential participants (Group Health/UW, Marshfield,
Northwestern), and surveys of potential participants (Vanderbilt)
and participants (Group Health/UW). While there was no formal
attempt to coordinate either the content of the information pro-
vided to stakeholders or the specific questions posed, all sites did
discuss the NIH GWAS data-sharing policy and/or the likely de-
position of data into the national data repository dbGaP, as well as
security precautions taken to protect the confidentiality of shared
data. Four of five sites also asked about what informed-consent
requirements should be implemented for GWAS-related data
sharing, as well as stakeholders’ attitudes with respect to with whom
(investigators, organizations) data might be shared (Table 3). Par-
ticipant re-consent for dbGaP deposition, mechanisms to ensure
third-party compliance with local oversight standards, and with-
drawing from research once data were shared were each only ad-
dressed by one or two sites, so we have a less comprehensive pic-
ture of stakeholder perspectives on these topics.
Limited data collected as part of our community consultation
activities suggests that participants and potential participants hold
generally favorable views on sharing of genetic and linked health
data in order to support and enable clinical research. A majority
[61% (n = 27/44)] of research participants interviewed at the Mayo
Clinic expressed neutral reactions to the sharing of research data
(including sharing of data with federal entities), while 30% (n = 13/
44) expressed negative views, and 9% (n = 4/44) were positive.
Participants in focus groups conducted at Group Health, North-
western, and Marshfield (n = 161 individuals participating in 20
focus groups across all three studies) also expressed support for
broad data sharing, particularly where such sharing might pro-
mote more efficient use of study resources (Lemke et al. 2010;
Trinidad et al. 2010; McCarty et al. 2011b). Furthermore, most
respondents [69.5% (n = 2800/4040)] to a Vanderbilt survey of its
faculty and staff (who overwhelmingly use Vanderbilt University
Medical Center and so constitute at least some potential partici-
pants in the BioVU repository, though their views on data sharing
may well be different from those of other potential participants)
reported that sending data to a national database would make no




[18.5% (n = 745/4040)] said it would make them more likely to
participate (KB Brothers, DR Morrison, and EW Clayton, in prep.).
Finally, at Marshfield Clinic, after dbGaP-related data sharing was
outlined in a newsletter mailed to all 20,000 biobank participants,
only one request for withdrawal was received.
Where stakeholders’ views on dbGaP-related data sharing
were explored in greater detail, some participants expressed con-
cern about the possibility of the federal government’s storing and
controlling access to their genetic and health-related data. How-
ever, it was not clear to what degree, if any, such concerns influ-
enced potential participants’ willingness to participate in research.
In a four-day deliberative community engagement exercise held
with 21 Olmsted County, Minnesota, residents to guide planning
of the Mayo Clinic Biobank, participants endorsed data sharing as
long as the appropriate safeguards were put in place and approved
by the institution participants had entrusted with their data and
samples (in this case, the Mayo Clinic). Focus group discussions at
Group Health, Northwestern, and Marshfield also suggested that
where concerns about federal control were expressed, they were
often balanced by trust in the home institution and confidence in
the ability of local investigators to ensure that any data shared with
federal entities would be suitably protected (Trinidad et al. 2011).
Participants at Northwestern strongly recommended increased
efforts to educate the public about the uses of data and general
outcomes as a means to increase public trust (Lemke et al. 2010). At
Group Health, where the IRB determined that re-consent for
dbGaP data sharing was required, 152 (11%) of 1340 cognitively
intact study participants declined to give permission for such
sharing, and 90% of 365 who had re-consented said that it was very
or somewhat important that they had been asked for their per-
mission (Ludman et al. 2010).
Another major theme identified by several of the study sites
was stakeholders’ discomfort with the possibility that their data
might be shared with commercial entities. At Marshfield, the
Community Advisory Board expressed the desire that, where
possible, Marshfield would work collaboratively with industry to
advance the community’s interests. As with federal data sharing, it
was unclear whether or not participants who expressed concerns
about commercial data sharing would withdraw from the research
if they were informed that it is allowable following deposition into
dbGaP unless explicitly precluded in the informed consent. In the
Group Health survey of participants who had re-consented for
dbGaP submission, slightly more than 40% (n = 151/365) expressed
concerns about the for-profit use of their shared data (Ludman
et al. 2010). Yet, as mentioned above, nearly 90% of these partic-
ipants re-consented to broad data sharing, suggesting that, al-
though these concerns exist, at least in some cases they are out-
weighed by participants’ desire to contribute to research.
Discussion
Participant perspectives on data sharing deserve careful consider-
ation by policymakers, funders, and researchers. Although the
eMERGE community engagement activities described above were
generally conducted long after participants were enrolled into the
different studies, in many cases the sort of limitations desired by
participants was incorporated into the original informed-consent
document. For example, some eMERGE institutions made assur-
ances in the original consent that data will not be used by for-profit
companies. Per the NIH GWAS data-sharing policy, institutional
certification for submission to dbGaP must ensure that data-use
limitations reflect what was communicated to the research par-
ticipants in the informed-consent process about how their data
may be used and who will have access to it (National Institutes of
Health 2007). Investigators who submit data access requests for
study data sets through dbGaP sign a Data Use Certification and
Table 3. Methods used and topics addressed with participants and community advisory boards
Institution GHC Marshfield Mayo Northwestern Vanderbilt
Consultation method(s) Focus groups
(n = 79), telephone
survey (n = 365),
consensus panel
(n = 13)




Board (CAB, n = 20)
Interviews (n = 50),
deliberative
engagement







CAB (n = 25)
Web survey
(n = 4037),
CAB (n = 10)
Topics addressed
NIH GWAS data-sharing
policy/deposition of data in
national database dbGaP
X X X X X
Benefits of sharing de-identified
genotypic and phenotypic data
X X X X
Informed consent requirements X X X X






X X X X
Sharing with for-profit
organizations
X X X X
Security to prevent unauthorized
access and protect
confidentiality
X X X X X
Mechanisms to ensure third-party
compliance with local standards,
especially with regard to
secondary use and/or privacy
X X






agree to abide by these data-use limitations (https://dbgap.ncbi.
nlm.nih.gov/aa/wga.cgi?view_pdf&stacc=phs000007.v2.p1). How-
ever, for many NIH grant-making programs with finite funds
available, breadth of data sharing permitted is a factor considered in
funding decisions (http://grants.nih.gov/grants/gwas/GWAS_faw.
htm). Studies at sites that are not able to share data broadly might be
considered a lower priority for funding, a result which some might
object to as inappropriate policy. This raises important ethical
challenges and questions about how much control individual sites
should be able to retain over their shared data sets, given their re-
sponsibilities as the sole steward of data and biological materials
supplied by the original participants.
The policy also anticipates that, in some cases, circumstances
beyond the control of the investigators may preclude submission
of GWAS data to dbGaP. For example, certain groups (e.g., tribal
groups or other potentially identifiable population-based cohorts)
may wish to maintain control over the data and prohibit sub-
mission to dbGaP altogether. In these rare cases, the investigator is
expected to provide in the grant application an explanation for
why submission to dbGaP is not possible. The appropriate NIH
Institute or Center will then consider this explanation when
making the funding decision (National Institutes of Health 2007).
Information about how many requests for such limitations to or
exclusions from data sharing have been submitted to NIH, how
many have been accommodated, and what influence, if any, this
has had on funding decisions is not available but would be helpful
to determine whether and to what extent this creates a problem for
investigators.
It also remains unclear whether institutions submitting data
to dbGaP can require review by a secondary user’s (requestor’s) IRB
based on assurances made in the original consent or for certain
types of data (e.g., those associated with a stigmatized disorder,
such as substance abuse). Typically, requestors who are obtaining
de-identified data from dbGaP are not considered to be conducting
human subjects research (Office of Human Research Protections
2008) and so no IRB review is required for their research. However,
because DNA is uniquely identifying (Lin et al. 2004; Homer et al.
2008), in order to protect the privacy of certain groups and to re-
spect the wishes of participants, some investigators have requested
an additional layer of ethical review prior to the downstream use of
certain data sets. There are a few examples of this restriction being
implemented in dbGaP (see e.g., Framingham SNP Health Associ-
ation Resource, http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000007.v13.p5 and CIDR: Collabora-
tive Study on the Genetics of Alcoholism Case Control Study,
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_
id=phs000125.v1.p1), but decisions about when such requests will
be accommodated are made by each Institute or Center (IC) and
may depend on the uniqueness of the data resource and whether
alternative solutions are possible.
Consistent policies within and between institutions are
needed so that investigators, IRBs, and other institutional officials
know what level of protection they can promise to participants,
and participants can make decisions based on accurate and
truthful information. Clearer guidance is also needed from NIH as
a whole and its individual Institutes and Centers so that in-
vestigators and institutions can know what to expect when sub-
mitting grant applications and requests to limit data access. Cre-
ating data-use limitations that are responsive to participants’
concerns shows respect for those who contribute to research and
may increase trust, resulting in greater research participation.
However, investigators may believe that they cannot place such
limits on data sharing if it precludes them from funding oppor-
tunities. There are many benefits to broad data sharing that the
NIH GWAS data-sharing policy promotes. Our preliminary re-
search with eMERGE participants suggests that, although most are
willing to share their data, there is a strong desire for some data-use
limitations. Requiring all participants to agree to unrestricted data
release may result in certain groups choosing not to participate in
research, which could create subject bias and influence the ability
of investigators to identify disease variants relevant to the pop-
ulation at large (Kohane and Altman 2005; McGuire and Gibbs
2006).
Conclusion
Data sharing creates novel challenges for researchers and in-
stitutions, both ethically and administratively. Solutions can be
developed ad hoc, but this approach runs the risk of data sharing
being rushed and implemented without full consideration and
may lead to poor decisions and outcomes. The eMERGE Consor-
tium experience illuminates some of the challenges associated
with implementing the NIH GWAS data-sharing policy. Many of
these challenges can be addressed by clearer guidance from NIH to
ensure that the ethical safeguards built into the policy are upheld
without significant burden to investigators or institutions. How-
ever, in some cases, the NIH may need to change its policies and/or
practices.
The eMERGE Consortium experience also illustrates the need
for institutions and researchers to adjust to a new status quo in
research where data-sharing requirements are the norm. Processes
to facilitate data sharing among institutions and IRBs should
be developed and ethical challenges should be addressed pre-
emptively. Researchers and institutions must also be ready to share
data consistent with the NIH GWAS data-sharing policy. A process
should be in place to ensure compliance with the policy, and rel-
evant expertise should be available to assist researchers and review
protocols ahead of time. To the extent possible, harmonization
across sites, especially for large consortia, should be a priority. Fi-
nally, in order to address community concerns, researchers should
integrate community engagement and ethics evaluation into their
study design and budget. Ultimately, institutions and researchers
must meet their stewardship obligations by developing policies
and practices that nurture trustworthiness in relationships with
participants and communities.
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